USPTO serial 79429604
COMPASS
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- LAPTER, ALAIN J
- Law office
- TMEG LAW OFFICE 105
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with COMPASS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rexford Brabson
Rexford Brabson T-Rex Law, P.C.7040 Avenida Encinas #104-333Carlsbad, CA 92011United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Nutritional and nutraceutical supplements formulated to support ocular health, slow disease progression, and enhance retinal function, particularly for individuals diagnosed with late-stage macular disease or age-related macular degeneration (AMD). | ACTIVE | — |
| 009 | Downloadable software leveraging artificial intelligence (AI) algorithms for capturing, analyzing, and monitoring retinal images to assess disease progression, generate personalized treatment recommendations, and facilitate clinical decision-making; scientific and laboratory apparatus (not for direct clinical use) for collecting, interpreting, and managing research data related to ophthalmic treatments and disease models. | ACTIVE | — |
| 010 | Minimally invasive laser-based apparatus for the treatment and management of late-stage macular disease, age-related macular degeneration (AMD), and low central vision, designed to improve or maintain visual acuity and patient quality of life; diagnostic instruments and devices, including handheld or wearable artificial intelligence (AI)-powered tools, for detecting, monitoring, and analyzing ocular conditions such as macular degeneration and other retinal disorders (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); interventional medical devices tailored to stabilize or restore sight in individuals suffering from low vision due to advanced retinal pathology. | ACTIVE | — |
| 040 | Custom manufacturing of ophthalmic devices, laser-based treatments, diagnostic equipment, and related components for third parties, ensuring adherence to quality, safety, and regulatory standards (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations). | ACTIVE | — |
| 041 | Arranging and conducting seminars, webinars, workshops, and training programs for healthcare professionals and researchers on diagnosing, treating, and managing late-stage macular disease, age-related macular degeneration (AMD), and associated retinal conditions; publishing and distributing printed and electronic educational materials on best practices for ocular health maintenance, preventative eye care, and implementation of artificial intelligence (AI)-driven diagnostic and therapeutic approaches. | ACTIVE | — |
| 042 | Clinical and scientific research in the field of ophthalmology, focusing on the development, validation, and optimization of laser-based therapies, diagnostic devices, and minimally invasive interventions for retinal diseases; research and development (R&D) services aimed at advancing artificial intelligence (AI)-driven healthcare solutions, including predictive modeling, disease progression tracking, and outcome measurement in macular disease; providing online, non-downloadable software (SaaS/PaaS) with artificial intelligence (AI)-enabled analytics to support clinical decision-making, real-time patient monitoring, and health data management for improved vision care outcomes; technical consulting in the field of medical technology integration, including artificial intelligence (AI) algorithms, data analytics, and device interoperability for optimized patient care. | ACTIVE | — |
| 044 | Providing minimally invasive ocular treatments, including laser-based therapies, to improve or stabilize visual acuity in patients with late-stage macular disease; telehealth and remote patient monitoring services that utilize artificial intelligence (AI)-driven platforms to guide clinical evaluations, detect disease changes, and optimize treatment regimens for individuals with low central vision; medical consultancy to physicians, clinics, and healthcare institutions on the adoption and integration of laser therapy, artificial intelligence (AI)-empowered diagnostic tools, and evidence-based nutraceutical protocols for retinal disease management. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Compass HealthAI Applications Inc.
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named COMPASS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 1, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 3, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 3, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 3, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 1, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 30, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 30, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 18, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 30, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 30, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 19, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 18, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 14, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 14, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 7, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |